Terminal2 · Diagnosis Card #04

Liver Cancer (HCC)

An evidence-based clinical reference for clinicians, families, and patients navigating hepatocellular carcinoma at end of life — two diseases at once, hepatic encephalopathy, malignant ascites, variceal hemorrhage, pruritus, and the pharmacological discipline required when the organ that processes every medication is the organ that is failing.

S01 Everyone

What Is It

Definition, mechanism, and the clinical reality of HCC at end of life. What the hospice team needs to understand on day one — two diseases in one patient.

Global Cases/Year
~850K
~850,000 new cases worldwide — second leading cause of cancer death globally.[1]
Cirrhosis Background
80–90%
80–90% of HCC arises in cirrhotic livers — two diseases simultaneously.[6]
AFP Elevation
~60–70%
AFP elevated in ~60–70% of cases — used for monitoring, not diagnosis alone.[3]
Child-Pugh C Prognosis
Wks–Mos
Child-Pugh C = weeks to months. All systemic therapy contraindicated.[2]

Hepatocellular carcinoma (HCC) is cancer that starts inside the liver cells themselves — not cancer that has spread from somewhere else. It represents approximately 90% of all primary liver cancers and accounts for roughly 700,000–800,000 deaths per year globally, making it the second leading cause of cancer death worldwide.[1]

The liver performs hundreds of essential functions: filtering blood, making clotting proteins, processing medications, and producing bile. HCC disrupts all of these simultaneously — which is why patients often become sick in multiple ways at once.[7]

What makes HCC especially complex is that it almost always occurs on a background of existing liver disease. About 80–90% of cases arise in the setting of cirrhosis.[1] Two diseases are happening at the same time — the tumor and the failing liver — and both drive the clinical picture. HCC requires assessing liver reserve (Child-Pugh, MELD) alongside tumor stage — prognosis is driven by both.[2]

🧭 Clinical framing

Think of it this way — the liver is like a house that's already partially flooded. Now there's also a fire inside. We're treating both at the same time. That's why this can feel so complicated — because it is. HCC is unique among cancers: liver failure is often the cause of death — not tumor burden alone.[14] Most medications are metabolized hepatically — dosing is never routine.[35]

From the Field
Waldo Rios, NP
Hospice NP · 12+ Years
"This disease lives inside a broken liver. You can't treat one and ignore the other. Every comfort decision has a hepatic layer to it. Think liver first. Always."
— Waldo, NP · Terminal2
S02Clinician

How It's Diagnosed

Diagnostic workup, BCLC staging, and what to look for in hospice records. Most patients arrive with an established diagnosis — this section helps you read it.

HCC is one of the few cancers that can often be diagnosed without a biopsy, based on its vascular signature on imaging alone — arterial enhancement followed by venous washout on CT or MRI has sensitivity ~60% and specificity 96–100%.[3]

Surveillance & Diagnostic Workup
  • Ultrasound surveillance every 6 months in all cirrhotic patients — early detection achieves curative therapy candidacy in 40–50% of patients[7]
  • Multiphase CT or MRI with contrast: Arterial hypervascular enhancement + venous washout = pathognomonic for HCC — often no biopsy required[3]
  • LI-RADS classification system used to categorize liver lesion risk
  • AFP >400 ng/mL in cirrhosis: Highly suspicious, often diagnostic[3]
  • Biopsy reserved for indeterminate lesions only
What to Look for in Hospice Records
  • Child-Pugh class (A/B/C): This single classification drives every prescribing decision[2]
  • MELD score: >20 = advanced liver failure[18]
  • TIPS shunt presence: Encephalopathy risk multiplied — mandatory lactulose/rifaximin[19]
  • Prior TACE/TARE procedures: Liver reserve affected by each treatment[12]
  • Prior variceal banding or beta-blocker prophylaxis
  • AFP trend: Rapidly rising = accelerating disease[3]
  • INR trajectory: Your prognosis barometer — 1.8 to 2.1 to 2.4 is the arc of dying liver function[18]
BCLC Staging — Barcelona Clinic Liver Cancer

The BCLC system is the global standard for HCC staging. It simultaneously accounts for tumor burden, liver reserve, and performance status.[2]

StageDescriptionPreferred TreatmentPrognosis
0 — Very EarlySingle <2 cm, Child-Pugh AResection or Ablation>5 yr survival possible
A — EarlySingle or ≤3 nodules <3 cm, CP-A/BResection / Transplant / Ablation3–5 yr median
B — IntermediateMulti-nodular, no vascular invasionTACE / TARE2–3 yr median
C — AdvancedPortal vein invasion or extrahepatic spreadSystemic therapy~1 yr median
D — TerminalChild-Pugh C, ECOG PS 3–4Best supportive care / HospiceWeeks to months

💡 For families

💡 Para las familias

Most diagnostic workup is already complete by the time your loved one enters hospice. The focus now is entirely on comfort. The staging information above helps the hospice team understand what your person has been through — every treatment, every test, every decision that led to this point matters to how we care for them now.

Próximamente en español.

S03Everyone

Causes & Risk Factors

Modifiable and hereditary risk factors. Relevant for family conversations, genetic counseling referrals, and answering "why did this happen?"

HCC rarely arises in a normal liver. The common denominator across nearly all cases is: chronic inflammation → fibrosis → cirrhosis → carcinogenesis.[1]

Primary Risk Factors
  • Hepatitis B (HBV): Most common cause globally; 15–20× increased risk. HBV vaccination is the most effective cancer prevention tool in the world. Can cause HCC even without cirrhosis via direct oncogenic DNA integration.[5][6]
  • Hepatitis C (HCV): Most common cause in US/Western world. Direct-acting antivirals now cure >95% — HCC risk persists even after cure in patients with established cirrhosis.[6]
  • MASLD/MAFLD: Metabolic-associated fatty liver disease — fastest growing cause of HCC in the US. Obesity, type 2 diabetes, metabolic syndrome.[4]
  • Alcohol-related liver disease: Alcohol-related cirrhosis — 3× increased risk. Important for family dynamics — see Psychosocial section.[16]
  • Aflatoxin B1 exposure: Contaminated grain and peanuts — major cause in sub-Saharan Africa and Southeast Asia. Synergistic with HBV.[1]
Hereditary & Additional Factors
  • Hereditary hemochromatosis: Iron overload drives cirrhosis and carcinogenesis
  • Wilson's disease: Copper accumulation with hepatic injury
  • Primary biliary cholangitis: Chronic cholestatic liver disease
  • Male sex: 3–4× higher incidence than women[1]
  • Type 2 diabetes & obesity: Independent HCC risk factors, especially combined with MAFLD[4]
  • Smoking: Modifiable co-factor amplifying risk in cirrhotic patients[4]

⚕ Health Disparities

HCC disproportionately affects Asian Americans, Pacific Islanders, Black Americans, and Hispanic Americans — reflecting HBV and HCV prevalence patterns and differential access to antiviral treatment. Asian American men have the highest HCC incidence of any group in the US. Male predominance 3–4:1 across all groups.[1][17]

❤️ For families: "Why did this happen?"

Liver cancer develops because of long-standing liver injury — from hepatitis, from metabolic disease, from alcohol, or from causes no one could have prevented. This is a disease, not a verdict. No one is to blame. The focus now is comfort, presence, and quality time.

S04ClinicianEveryone

Treatments & Procedures

What disease-directed treatments this patient may have received or may still be receiving. Understanding prior therapy helps anticipate complications and interpret the patient's trajectory.

Curative Intent (BCLC 0/A)
Surgical Resection

Standard for solitary tumors with preserved hepatic reserve. Only 10–15% of patients are eligible. 5-year survival 40–70% in selected patients. Know if prior resection occurred.[2]

Liver Transplantation

Milan criteria (single ≤5 cm or ≤3 nodules each ≤3 cm) — ~70% 5-year survival. Most effective treatment: cures both tumor and cirrhosis. Know if patient was evaluated, listed, or delisted and why.[2]

Ablation (RFA/Microwave/Cryo)

Comparable to resection for tumors <3 cm. Preferred when surgery not feasible. Radiofrequency, microwave, or cryoablation for small tumors in non-surgical candidates.[2]

Locoregional (BCLC B–C)
TACE — Transarterial Chemoembolization

Intra-arterial doxorubicin + embolization. Standard of care for BCLC-B. DEB-TACE reduces systemic exposure.[13] Adjuvant TACE post-resection improves OS/DFS in microvascular invasion.[12] Each treatment reduces liver reserve — know how many done and when last performed. Contraindicated in CP-C or active variceal bleed.[2]

TARE — Y-90 Radioembolization

Yttrium-90 microspheres to tumor-feeding arteries. BCLC B–C including portal vein thrombosis (where TACE is contraindicated). Better tolerated than TACE. Useful for downstaging to transplant candidacy. Know if done.[7]

Systemic Therapy (BCLC C)
Current First-Line: Atezolizumab + Bevacizumab (IMbrave150)
RCT

IMbrave150 established atezo+bev as preferred first-line. Median OS 19.2 months vs 13.4 months with sorafenib (HR 0.66; p<0.001).[11] Requires adequate liver reserve and ECOG ≤1.[10]

  • Lenvatinib (REFLECT): Non-inferior to sorafenib (mOS 13.6 vs 12.3 mo; HR 0.92). Better ORR 24.1% vs 9.2%. Use when atezo+bev contraindicated.[9]
  • Sorafenib (SHARP, 2008): First approved systemic agent. mOS 10.7 months vs placebo (HR 0.69). Now second-line option.[8]
  • Regorafenib and ramucirumab: Second-line after sorafenib/lenvatinib[7]

⚠ Bevacizumab Warning

Increases variceal hemorrhage risk. Require EGD with variceal eradication before starting. Contraindicated in active GI bleeding.[10] Know what the patient received, when, and what reserve remains — each locoregional treatment and each systemic therapy line depletes liver reserve.

S05Clinician

When Therapy Makes Sense

Evidence-based criteria for continuing disease-directed therapy. This is not about giving up or holding on — it's about reading the data correctly.

  1. 01
    Child-Pugh A or B7 or below: Adequate hepatic reserve for systemic therapy — Child-Pugh C is an absolute contraindication to all systemic therapy.[2]
  2. 02
    ECOG PS 0–1: BCLC Stage A, B, or C with functional reserve. Patient is ambulatory and self-caring for >50% of waking hours.[7]
  3. 03
    BCLC B with preserved liver function — TACE/TARE appropriate: 2–3 year median OS, well-established evidence.[2]
  4. 04
    Atezolizumab + bevacizumab first-line in BCLC C with Child-Pugh A: IMbrave150 — strongest evidence base in systemic HCC therapy. Median OS 19 months.[10][11]
  5. 05
    Resection or transplant candidacy in BCLC 0/A: Curative intent remains possible. Milan criteria apply.[2]
  6. 06
    Patient goals explicitly include life-prolongation with full prognosis understanding and adequate performance status. Shared decision-making is the foundation.[15]

📋 Clinical note

HCC treatment decisions are inseparable from liver function assessment — the same tumor burden in a Child-Pugh A patient and a Child-Pugh C patient represents completely different clinical realities and completely different conversations.

S06Clinician

When It Doesn't

Knowing when treatment stops helping is not clinical failure. It is the most important clinical skill in this disease.

🔴 Clinical honesty matters here

Many HCC patients arrive to hospice late. Knowing when to stop sooner protects dignity and reduces futile suffering. These are not defeat criteria — they are clarity criteria.

  1. 01
    Child-Pugh C: Terminal liver disease regardless of tumor stage. All systemic therapies are contraindicated and do not improve survival.[2]
  2. 02
    ECOG ≥2 / BCLC D: No survival benefit from tumor-directed therapy in patients spending >50% of waking hours in bed.[7]
  3. 03
    Refractory ascites: Paracentesis frequency >every 1–2 weeks with no diuretic response = terminal trajectory regardless of treatment.[22]
  4. 04
    Grade 3–4 hepatic encephalopathy: Aggressive tumor treatment provides no benefit and accelerates deterioration.[19]
  5. 05
    Hepatorenal syndrome (HRS): Onset signals end-stage portal hypertension. Median survival 1–2 weeks without terlipressin/albumin. Name it to the family.[22]
  6. 06
    Estimated survival <3 months: Tumor-directed therapy generates toxicity without survival benefit. Hospice enrollment appropriate and beneficial.[15][17]
  7. 07
    Patient goals shift to comfort: When quality of life and time at home override quantity — and after the clinician has ensured it's a fully informed choice.[15]

📋 Clinician note

HCC patients are consistently under-referred to palliative care. Barriers include prognostic uncertainty and clinician discomfort — not just patient refusal.[15] Integrate early. Don't wait for "nothing more to do."

S07Everyone

Out-of-the-Box Approaches

Evidence-graded integrative, interventional, and complementary approaches. Grade A = RCT; B = multi-observational/meta-analysis; C = limited clinical, strong preclinical; D = expert opinion.

Acupuncture / Acupressure
Grade B
1–2× weekly; PC6 and ST36 acupoints most studied
Systematic review of palliative cancer care: significant benefit for pain and nausea reduction.[33] RCT evidence supports acupressure for CINV control.[34] Well-tolerated; minimal contraindications in most patients.
Mistletoe (Viscum album / Iscador)
Grade C
SC injection: 1–30 mg, 2–3× weekly; dose escalated by provider
Lectins and viscotoxins have cytotoxic and immunomodulatory properties. QoL benefit in cancer patients.[31][32] HCC-specific RCT data absent. Requires refrigerated preparation.
Melatonin
Grade C
3–20 mg orally at bedtime
Exerts anti-tumor effects in HCC via apoptosis induction, oxidative stress reduction, and modulation of cancer signaling pathways.[28] Strong preclinical data; limited clinical RCTs. Generally well-tolerated. May improve sleep and reduce cancer fatigue.
Low Dose Naltrexone (LDN)
Grade C
1.5–4.5 mg nightly PO (compounded)
Transiently blocks opioid receptors → compensatory endogenous opioid upregulation + TLR4 antagonism → immune modulation.[29] Enhances dendritic cell maturation.[30] No HCC-specific RCTs. Caution in opioid-dependent patients — competing doses may precipitate withdrawal.
Curcumin Phospholipid Complex
Grade C
Phospholipid-bound form (Meriva): 500–1500 mg/day with food
Anti-inflammatory and pro-apoptotic in HCC cell lines.[26] Poor native bioavailability; phospholipid complexes substantially improve absorption. Caution: may interfere with lenvatinib via EGFR pathway competition.[27] Discuss with oncology before combining with active systemic therapy.
S08Everyone

Natural & Herbal Options

Evidence grading, dosing where supported, drug interaction flags, and explicit contraindications specific to HCC and liver failure.

⚠ Liver disease changes everything

Most herbals are metabolized hepatically. In HCC with cirrhosis, drug interactions and hepatotoxicity risks are amplified. "Natural" does not equal safe in this population.

From the Field
Waldo Rios, NP
Hospice NP · 12+ Years
"Patients are going to use supplements whether we ask or not. The conversation is: 'I want to know what you're taking — not to judge you, but because some of these interact with your pain medications and blood thinners.' Say it plainly. Most of the time they're relieved someone asked."
— Waldo, NP
Herb / Supplement Evidence Grade Typical Dose Potential Benefit ⚠ Interactions / Contraindications
Milk Thistle / SilymarinGrade B140–420 mg TID, standardized 70–80% silymarinHepatoprotective, antioxidant, antifibrotic via MAPK/mTOR/Akt. Anti-HCC activity preclinically.[23][24]Inhibits CYP2C9 & CYP3A4 — may increase sorafenib, warfarin, statin levels. Monitor INR closely. Caution Asteraceae allergy.[23]
GingerGrade B500–1000 mg TID for nausea; 250 mg QID for CINVAntiemetic via 5-HT3 antagonism and gastric motility effects.[34]Mild antiplatelet — caution coagulopathic HCC with elevated INR. May potentiate anticoagulants at doses >4g/day. Safe at standard doses.
Dandelion RootGrade C500–1000 mg TID (dried root extract)Mild diuretic and hepatic support. Preclinical anti-inflammatory activity.Additive diuretic effect with furosemide/spironolactone — monitor electrolytes. ⚠ CONTRAINDICATED in biliary obstruction — stimulates bile flow, can cause pain crisis.
Turmeric / Curcumin PhospholipidGrade CMeriva 500–1500 mg/day with fat-containing mealAnti-inflammatory and pro-apoptotic in HCC cell lines via NF-κB suppression.[26]Antiplatelet/anticoagulant — risky in coagulopathic HCC. CYP competition with lenvatinib.[27] Contraindicated in active GI ulcer or biliary obstruction.
🚫 Hepatotoxic — Absolutely Contraindicated in HCC / Liver Disease
  • Kava (Piper methysticum): Documented risk of fulminant hepatic failure. Banned or restricted in multiple countries. Absolutely contraindicated in any liver disease.
  • Comfrey (Symphytum officinale): Contains pyrrolizidine alkaloids (PAs) — directly cause hepatic veno-occlusive disease. Never use internally in liver disease.
  • PA-containing herbs (Borage, Coltsfoot, Senecio, Heliotrope, Bush tea): Same mechanism as comfrey. Cumulative PA exposure causes irreversible liver damage.
  • Chaparral (Larrea tridentata): Associated with acute and chronic liver failure requiring transplantation. No safe dose in liver disease.
  • High-dose Green Tea Extract (EGCG capsules >800 mg/day): Multiple hepatotoxicity case reports. Differs from brewed green tea. Avoid supplemental EGCG in HCC/cirrhosis.
S09Everyone

Timeline Guide

A guide, not a prediction. Active dying in HCC is shaped by both tumor burden and liver failure — often both happening simultaneously.

This applies to patients who have stopped disease-directed treatment. HCC trajectory is shaped by liver reserve, tumor burden, portal hypertension, and comorbidities.[2]

YRS
Years Before Death — Early-Stage Disease
  • Often still receiving treatment (surgery, TACE, systemic therapy); ECOG PS 0–1[7]
  • Compensated cirrhosis — liver handling most functions; fatigue, mild RUQ discomfort
  • AFP and tumor size trending on serial labs/imaging
  • Best time for early palliative care integration and goals-of-care conversation[15]
MOS
Months Before Death — Declining Reserve
  • Treatment no longer controlling disease or no longer tolerated
  • Increasing ascites — paracentesis every 2–4 weeks[22]
  • First episodes of hepatic encephalopathy — confusion, personality change, reversed sleep cycle[19]
  • Deepening jaundice; rising bilirubin; INR beginning to climb
  • ECOG PS 2–3; weight loss, sarcopenia accelerating[14]
  • Hospice referral should be initiated now[15]
WKS
Weeks Before Death — Decompensation
  • Refractory ascites — paracentesis every 1–2 weeks; consider tunneled drain
  • Encephalopathy more frequent; marked personality change and disorientation[19]
  • Severe pruritus; deep jaundice; dyspnea from elevated diaphragm[14]
  • INR >2.0–2.5; platelet count falling; variceal bleed risk elevated[14]
  • Oral intake severely diminished; ECOG PS 3–4; bedbound most of day
  • Opioids for comfort; begin de-escalation discussion with family
DAYS
Days Before Death — Imminent Dying
  • Unresponsive or minimally arousable; terminal encephalopathy Grade IV[19]
  • Cheyne-Stokes or irregular respirations; mottling at knees/feet progressing proximally
  • Terminal secretions ("death rattle"); extremities cool; no oral intake
  • GI bleeding may occur (hematemesis, melena) — prepare family now
  • Comfort medications via SQ/IM route; discontinue all labs and non-comfort meds
HRS
Hours Before Death — Active Death
  • Agonal respirations (gasping); prolonged apnea periods; jaw relaxed
  • Eyes may be partially open with fixed gaze; no gag reflex
  • Mottling extending to trunk; grayish-blue skin color changes
  • Heart rate irregular; radial pulse absent; carotid may persist briefly
  • Family presence: normalize, prepare, be present — sit down, breathe, hold their hand
S10Clinician

Medications to Anticipate

Symptom-targeted pharmacology for HCC. What to have in the comfort kit, what to titrate first, and what liver failure changes about every dose.

⚠ Liver failure pharmacology

Most opioids and benzodiazepines are hepatically metabolized. Half-lives prolonged 2–4× in decompensated cirrhosis. Start at 50% of standard doses, extend dosing intervals, and monitor for sedation before titrating.[35]

DrugIndicationStarting DoseLiver Failure Notes
MorphinePain, dyspnea1–2 mg q4h PO/SL⚠ Reduce 50%; M6G accumulates → sedation, myoclonus. PO/SQ/IV[35]
HydromorphonePain (morphine alternative)0.2–0.4 mg q4h PO⚠ Preferred in renal impairment; reduce 25–50% in hepatic failure. PO/SQ/IV[35]
HaloperidolNausea, agitation, terminal delirium0.5–1 mg q6–8h SQMonitor for EPS; hepatically metabolized. PO/SQ/IM
OndansetronNausea and vomiting4–8 mg q8h PO/SQ⚠ Max 8 mg/dose in Child-Pugh C — prolonged half-life. PO/SQ/IV
LactuloseHepatic encephalopathy30 mL BID–TIDTarget 2–3 soft BMs/day. Continue in active HE. De-escalate in imminently dying when comfort exceeds ammonia control. PO/NG/PR
RifaximinHE prophylaxis550 mg BIDMinimal systemic absorption; relatively safe. Reassess utility in terminal phase. PO
FurosemideAscites, fluid overload40 mg dailyMaintain 100:40 spironolactone:furosemide ratio. ⚠ Hold if creatinine rising — HRS risk. PO/IV[22]
SpironolactoneAscites (first-line)100 mg daily (up to 400 mg)First-line for cirrhotic ascites. Hold if hyperkalemia. PO[22]
LorazepamAnxiety, dyspnea, seizure0.5 mg q6h PO/SQ⚠ Use sparingly — can precipitate HE. Watch for paradoxical agitation. PO/SQ/IV/SL
HydroxyzinePruritus, mild anxiety25 mg TID–QID POPreferred over benzodiazepines for pruritus-related anxiety in this population. Reduce frequency in severe hepatic disease. PO/IM
MidazolamTerminal agitation0.5–1 mg SQ q1h PRN⚠ Accumulates in hepatic failure — begin conservatively, titrate to comfort. SQ/IV continuous

🚨 Comfort Kit — Variceal Hemorrhage Preparedness

Variceal hemorrhage is a possible terminal event in portal hypertensive patients. Educate the family at every visit — hematemesis (vomiting blood) and melena (black tarry stools) are red alerts. In hospice patients who have chosen to remain home: call the nurse immediately, stay present, do not leave the patient alone. Have midazolam drawn and labeled for catastrophic hemorrhage comfort management. Write this in the care plan and review it every visit.

S11Clinician

Clinician Pointers

High-yield clinical pearls for the hospice team. The things not in the textbook — learned at the bedside over years of clinical experience.

1
Know your West Haven grades cold
Grade I = subtle personality change, sleep disturbance. Grade II = asterixis, obvious confusion. Grade III = marked disorientation, stupor. Grade IV = coma. Grade I is what families call "just being tired."[19] Challenge that framing every time.
2
Measure abdominal girth weekly
>3 cm increase in 7 days despite diuretics = treatment failure. Document girth like a vital sign — it's your bedside prognostication tool in this disease.[22]
3
TIPS shunt = encephalopathy risk multiplied
TIPS diverts ammonia-rich portal blood directly into systemic circulation.[19] If your patient has a TIPS, lactulose and rifaximin are mandatory. Treat every confusion episode as HE until proven otherwise.
4
Variceal bleed = red alert for family
Educate every visit. Hematemesis (vomiting blood), melena (black tarry stool) = emergency.[14] In hospice patients: prepare the family that this may be how their person dies. Do not let it be a surprise.
5
Recognize HRS early
Rising creatinine + oliguria + no intrinsic renal disease in a patient with ascites = HRS until proven otherwise. Type 1 HRS: median survival 2 weeks without intervention.[22] Name it. Prepare the family.
6
SBP is easy to miss
Cirrhosis + ascites + fever + confusion = diagnostic paracentesis. PMN >250 cells/mm³ = SBP. Antibiotics prevent septic encephalopathy — still appropriate comfort medicine.[22]
7
INR trajectory is your prognosis barometer
Trending INR — 1.8, 2.1, 2.4 — is declining hepatic synthetic function. INR >2.0–2.5 → median survival often weeks.[18] Use this in your goals conversation. The trajectory IS the data.
8
Opioids in liver failure require calibration, not avoidance
Start morphine at 50% of standard dose, extend intervals to q6h initially, monitor eyes not the clock.[35] Untreated pain in HCC is unacceptable. Accumulation is the danger, not the drug.
From the Field
Waldo Rios, NP
Hospice NP · 12+ Years
"When you see the personality shift — irritability, apathy, that hollow look — that's not depression. That's not 'end of life personality.' That's ammonia in the brain. Treat it. Then explain it again to the family tonight."
— Waldo, NP · Terminal2
S12EveryoneClinician

Psychosocial & Spiritual Care

The symptom burden you can't see on a vitals sheet — shame, ambiguous loss, stigma, and the spiritual dimensions of liver disease.

Psychosocial distress in HCC is layered in ways unique to this diagnosis. The etiology of the underlying liver disease — alcohol, hepatitis C, metabolic syndrome — carries social and moral weight that other cancers do not. The hospice team must address this deliberately, not accidentally.

Disease-Specific Psychosocial Challenges
Alcohol-Related Liver Disease & Shame

A significant proportion of HCC patients have alcohol-related cirrhosis. Many carry profound shame and self-blame. Families sometimes carry anger at the patient for "causing" their own disease. Address this directly as a clinical problem, not a moral one — HCC is a disease, addiction is a disease, shame does not belong in a comfort care setting. The hospice team must model non-judgment explicitly.

Hepatitis C Stigma

HCV was and still is associated with IV drug use in many patients' histories. The same shame and judgment dynamics apply. Some patients have never told their families about their HCV status. The hospice team may be the first to know — or the first to address it openly. Create space. Do not force disclosure, but do not avoid the topic.

Encephalopathy & Ambiguous Loss

As hepatic encephalopathy progresses, the patient's personality changes. Families experience this as losing the person before they die. This is ambiguous loss — use the term. Give them permission to grieve a living person. The confusion comes and goes, which makes it harder: the person returns, then vanishes again. Name this pattern for the family. It is medical. It is not their fault.

The Speed Variable

HCC trajectory is unpredictable. A patient can be stable for months and then decompensate within days. Families are never fully prepared for the speed of the final decline. Set expectations at every visit: "Things can change quickly with liver disease. I want you to be ready for that possibility, even though right now things may feel stable."

Transplant Grief & Spiritual Dimensions
Guilt in Transplant-Listed Patients

Patients who were delisted or who declined transplant carry their own grief about that decision. Address it without defensiveness. The decision was made in context that may no longer apply. "You made the best decision you could with the information you had at the time" — say it out loud. They need to hear it from a clinician.

Cultural & Spiritual Dimensions of Liver Disease

In many cultures, the liver carries spiritual and cultural significance beyond its biology. Chinese medicine views the liver as the seat of the soul (Hun) and emotional regulation. Traditional Hispanic curanderismo has specific understandings of liver health and "bilis" (bile/anger connection). Cultural humility is essential — ask, don't assume.

Goals-of-Care Framing for HCC

"Dying at home without tubes, without confusion, without pain" is almost universally the operative goal in HCC. Name it, and build the entire care plan around protecting those three things. Confusion is manageable with lactulose. Pain is manageable with calibrated opioids. Tubes are preventable with advance planning. The goals conversation in HCC is not abstract — it is concrete and actionable.

Clinical Pearl

"The INR is not just a lab value in this disease. When you see it climbing — 1.8, 2.1, 2.4 — that is your cue to sit down with the family and say: the liver is getting weaker. We need to talk about what matters most right now. The trajectory IS the data. Use it."

S13FamilyEveryone

Family Guide

Plain language for families. Share, print, or read aloud at the bedside.

The liver is failing — and it affects everything at once. The liver runs hundreds of body processes. When it's failing because of cancer, problems show up in the brain, kidneys, skin, belly, and blood simultaneously. That's why it feels like everything is going wrong at once. Because it is. You are not imagining it. And you are not alone in managing it.

What You May See
  • Yellow skin and eyes (jaundice): Bile is building up because the liver can't process it. This causes severe itching. Tell the nurse if itching is not controlled — there are medications specifically for this.
  • Confusion or personality changes: Hepatic encephalopathy — ammonia from the failing liver affects the brain. Comes and goes. Do not take it personally — this is the disease, not your person.
  • Swollen belly from fluid (ascites): Positioning helps breathing — sitting up or at 30-degree angle. A drainage procedure is available for relief.
  • Sleeping most of the day: Normal and expected at this stage. Do not try to wake them for food or activity.
  • Nausea and loss of appetite: Small amounts of whatever sounds appealing. Ginger tea and ice chips are often better tolerated than full meals.
  • Itching that seems unbearable: Bile salts depositing in skin. Report at every visit — this symptom is very treatable and frequently undertreated.
How You Can Help
  • Position for comfort: Sitting up or at 30-degree angle reduces breathing difficulty from ascites
  • Sit quietly nearby and hold their hand: Familiar presence matters more than food or activity at this stage
  • Report confusion changes immediately: This symptom is medically manageable and you are the clinical team's eyes in the home
  • Do not push eating: Small offerings of favorite soft foods. Forcing causes suffering, not strength.
  • Tell the nurse about the itching at every visit until it is controlled — you have to be the advocate
  • If drainage catheter is in place: Follow the nurse's protocol. Call if output changes or tube stops draining.
📞 Call the nurse immediately if you see:

Vomiting blood or black tarry stools — call nurse immediately. Stay present. Do not leave patient alone.
Confusion that is sudden, severe, and different from baseline — call nurse.
Inability to be woken.
Signs of severe abdominal pain with rigid belly.

🙏 You are managing two diseases at once in one person, from inside a home, without medical training. What you are doing is extraordinary. The data on presence is clear: patients who have people with them do better — not just emotionally, but clinically. You are part of this care team whether you know it or not.

S14Everyone

Waldo's Top 10 Tips

Clinical field wisdom from 12+ years at the bedside. The things you learn after doing this long enough. Not guidelines — real.

  1. 01
    This disease lives inside a broken liver. You can't treat one and ignore the other. Every comfort decision has a hepatic layer to it. Think liver first. Always.
  2. 02
    The encephalopathy will fool you — and it will fool the family. Don't accept "he's always been like that." I've heard it a hundred times. It's ammonia. Run the number. Adjust the lactulose. Educate the wife.
  3. 03
    Ascites girth is not just a number on a flowsheet. It's your weekly prognostication. When it stops responding and you're draining every other week — the body is telling you something the chart cannot.
  4. 04
    Watch the INR. When it starts climbing — 1.8, 2.1, 2.4 — start the goals conversation. Don't wait for the crisis. The trajectory is the data.
  5. 05
    Opioids in liver failure are not contraindicated. They are calibrated. Start at half the dose. Double the time between doses. Watch the eyes, not the clock. Comfort is the goal.
  6. 06
    Families don't understand jaundice. Every visit. Explain it every visit. "The liver makes bile — bile is yellow — when it can't do its job, the yellow goes into the blood and skin." Draw it if you have to.
  7. 07
    Atezolizumab + bevacizumab changed the game — but not for Child-Pugh C patients. Don't let oncology language convince a terminal patient with decompensated disease that immunotherapy is a real option. Know the data. Protect them.
  8. 08
    When you see the personality shift — irritability, apathy, that hollow look — that's not depression. That's not "end of life personality." That's ammonia in the brain. Treat it. Then explain it again to the family tonight.
  9. 09
    Pruritus in liver cancer is one of the most undertreated symptoms I see in hospice. You have tools: ondansetron, hydroxyzine, rifampicin, cholestyramine. Use them. Don't walk out of that visit without a plan for the itch.
  10. 10
    The family is watching your face when you say "months." Watch your face. Your body language is the first translation of what you just said. Steady. Present. Honest. That is what they will remember when everything else is gone.
— Waldo, NP
REFClinician

References

43 peer-reviewed citations from PubMed. All PMIDs hyperlinked. Evidence levels assigned by article type.

1
Llovet JM, Zucman-Rossi J, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016;2:16018.
PMID 27158749 DOIReview
2
Vogel A, Cervantes A, et al. HCC: ESMO Clinical Practice Guidelines. Ann Oncol. 2018;29(Suppl 4):iv238–iv255.
PMID 30285213 DOIGuideline
3
Ayuso C, Rimola J, et al. Diagnosis and staging of HCC: current guidelines. Eur J Radiol. 2018;101:72–81.
PMID 29571804 DOIReview
4
Argenziano ME, Kim MN, et al. Epidemiology and clinical aspects of HCC in MAFLD patients. Hepatol Int. 2024;18(Suppl 2):922–940.
PMID 39012579 DOIReview
5
Chen CJ, Yang HI, et al. Risk of HCC across a biological gradient of serum HBV DNA level. JAMA. 2006;295(1):65–73.
PMID 16391218 DOIObservational
6
Tsai WL, Chung RT. Viral hepatocarcinogenesis. Oncogene. 2010;29(16):2309–2324.
PMID 20228847 DOIReview
7
Llovet JM, Montal R, Sia D, Finn RS. Molecular therapies and precision medicine for HCC. Nat Rev Clin Oncol. 2018;15(10):599–616.
PMID 30061739 DOIReview
8
Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced HCC (SHARP trial). N Engl J Med. 2008;359(4):378–390.
PMID 18650514 DOIRCT
9
Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line HCC (REFLECT). Lancet. 2018;391(10126):1163–1173.
PMID 29433850 DOIRCT
10
Finn RS, Qin S, Ikeda M, et al. Atezolizumab + bevacizumab in unresectable HCC (IMbrave150). N Engl J Med. 2020;382(20):1894–1905.
PMID 32402160 DOIRCT
11
Cheng AL, Qin S, et al. Updated IMbrave150 efficacy and safety data. J Hepatol. 2022;76(4):862–873.
PMID 34902530 DOIRCT
12
Chen ZH, Zhang XP, et al. Adjuvant TACE improves survival in HCC with microvascular invasion: meta-analysis. Eur J Surg Oncol. 2019;45(11):2188–2196.
PMID 31256949 DOIMeta-Analysis
13
Nam HC, Jang B, Song MJ. TACE with drug-eluting beads in HCC. World J Gastroenterol. 2016;22(40):8853–8861.
PMID 27833376 DOIReview
14
Premkumar M, Anand AC. Overview of complications in cirrhosis. J Clin Exp Hepatol. 2022;12(4):1150–1174.
PMID 35814522 DOIReview
15
Abasseri M, Hoque S, et al. Barriers to palliative care in HCC: literature review. J Gastroenterol Hepatol. 2023;38(7):1047–1055.
PMID 36634200 DOIReview
16
Lucey MR. Alcohol-associated cirrhosis. Clin Liver Dis. 2019;23(1):115–126.
PMID 30454826 DOIReview
17
Obri A, et al. Disparities in end-of-life care referrals in eligible HCC patients. Dig Dis Sci. 2023.
PMID 37289417Observational
18
Tapper EB, Lok AS. Diagnosis and management of cirrhosis: a review. JAMA. 2023.
PMID 37159031Review
19
Ridola L, Faccioli J, et al. Hepatic encephalopathy: diagnosis and management. J Transl Int Med. 2020;8(4):220–233.
PMID 33511048 DOIReview
20
Waghray A, Waghray N, Mullen K. Management of covert hepatic encephalopathy. J Clin Exp Hepatol. 2015;5(Suppl 1):S75–S81.
PMID 26041963Review
21
Eltawil KM, et al. Rifaximin vs. conventional oral therapy for HE: meta-analysis. World J Gastroenterol. 2012;18(8):767–777.
PMID 22371636Meta-Analysis
22
Biggins SW, Angeli P, et al. Diagnosis and management of ascites, SBP and HRS: AASLD 2021 practice guidance. Hepatology. 2021.
PMID 33942342Guideline
23
Wadhwa K, et al. Mechanistic insights into the pharmacological significance of silymarin. Molecules. 2022;27(16):5327.
PMID 36014565 DOIReview
24
Mastron JK, Siveen KS, et al. Silymarin and hepatocellular carcinoma: a systematic review. Anticancer Drugs. 2015;26(5):475–486.
PMID 25603021 DOISys Review
25
Post-White J, Ladas EJ, Kelly KM. Advances in the use of milk thistle. Integr Cancer Ther. 2007;6(2):104–109.
PMID 17548789 DOIReview
26
Ailioaie LM, et al. Curcumin and photobiomodulation in chronic viral hepatitis and HCC. Int J Mol Sci. 2020;21(19):7150.
PMID 32998270Review
27
Miyazaki M, et al. Curcumin-mediated resistance to lenvatinib via EGFR signaling in HCC. Cells. 2023;12(3):457.
PMID 36831279Observational
28
Mortezaee K, et al. Human HCC: protection by melatonin. J Cell Physiol. 2018.
PMID 29672851Review
29
Liu WM, et al. Naltrexone at low doses and its relevance to cancer therapy. Expert Rev Anticancer Ther. 2022.
PMID 35107043Review
30
Meng J, et al. Low dose naltrexone enhances maturation of bone marrow dendritic cells. Int Immunopharmacol. 2013;17(4):1014–1019.
PMID 24455776Observational
31
Schad F, et al. QoL in lung cancer patients receiving radiation and Viscum album. Radiat Oncol. 2023;18(1):47.
PMID 36879290Observational
32
Freuding M, et al. Mistletoe in oncological treatment: systematic review. Dtsch Arztebl Int. 2019;116:493–502.
PMID 32211937Sys Review
33
Wu X, et al. Effectiveness of acupuncture for palliative care of cancer: overview of systematic reviews. Sci Rep. 2015;5:16776.
PMID 26608664Sys Review
34
Molassiotis A, et al. Acupressure for chemotherapy-related nausea: RCT. J Pain Symptom Manage. 2014;47(1):12–25.
PMID 23602325RCT
35
Bateman DN. Opioid pharmacology and altered pharmacokinetics in liver failure. Crit Care. 2016.
PMID 27885969Expert Opinion
36
Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–1314.
PMID 29307467 DOIReview
37
Johnson PJ, et al. Assessment of liver function in HCC: the ALBI grade. J Clin Oncol. 2015;33(6):550–558.
PMID 25512453Observational
38
Ginès P, Krag A, et al. Liver cirrhosis. Lancet. 2021;398(10308):1359–1376.
PMID 34543610Review
39
Oura K, et al. Melatonin: a multifunctional molecule for HCC. Cells. 2021;10(12):3545.
PMID 34944053Review
40
Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of HCC. Gastroenterology. 2016;150(4):835–853.
PMID 26795574Guideline
41
Albillos A, Lario M, Álvarez-Mon M. Cirrhosis-associated immune dysfunction. J Hepatol. 2014;61(6):1385–1396.
PMID 25135860Review
42
Sapena V, et al. Hepatic tumour response using mRECIST in HCC undergoing TACE or radioembolisation. JHEP Rep. 2023.
PMID 37446035Observational
43
Adachi T, et al. Liver disease management and transplant considerations in HCC. Hepatol Res. 2020.
PMID 32939957Observational

terminal2.care content is for educational purposes and is not a substitute for clinical judgment. Based on articles retrieved from PubMed. © Terminal2 | terminal2.care

📝

Private Notes

Session notes — not saved to any server. Clears when you close the tab.

Use this space for visit notes, clinical reminders, or patient-specific observations. This text is stored only in your browser session.